A. Main safety issues

• ARIA-E

• ARIA-H

• infusion reactions

• hypersensitivity concerns

B. Monitoring workflow

• baseline MRI

• scheduled surveillance MRIs

• symptom-triggered MRI if needed

• when treatment pauses are considered

C. Risk modifiers

• APOE ε4 carrier status

• anticoagulant use

• prior hemorrhage burden or other imaging concerns

• other neurologic/medical issues

D. What I need to understand better

• Which MRI findings are absolute vs relative concerns?

• How conservative is this specific program?

• How are radiology findings communicated?

The official prescribing information includes boxed safety warnings around ARIA and includes monitoring guidance; the Alzheimer’s Association toolkit and AUR documents expand this into program-level workflow.